Trial Profile
A Single-arm, Open Label, Multi-centre Study Evaluating the Efficacy and Safety of Ig NexGen 10% in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jul 2016
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- Sponsors CSL
- 25 Jul 2016 New trial record